A phase III, multi-centre, randomized, double-blind, placebo-controlled study, with open-label follow on, to evaluate the efficacy, safety and tolerability of PDS502 in subjects with Premature Ejaculation (PE)

Registry ID

EUCTR2007-003171-39

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Plethora Solutions Ltd

Start date

2007-12-07

Completion date

2009-07-16

Last update

2026-08-16

Conditions

• Premature Ejaculation

Summary

To determine the effect of PSD502 on the Index of Premature Ejaculation (IPE) and intravaginal ejaculatory latency time (IELT).

Locations

• , , Czechia
• , , Hungary
• , , UK

Related clinical trials

• Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
• Pelvic Floor Therapies for Lifelong Premature Ejaculation
• The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation
• Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
• Ejaculatory and Orgasmic Dysfunction Registry
• Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients

View on source registry